Xtant Medical Hldgs Stock Net Asset
| XMS Stock | EUR 0.34 0.01 3.03% |
XTANT MEDICAL HLDGS fundamentals help investors to digest information that contributes to XTANT MEDICAL's financial success or failures. It also enables traders to predict the movement of XTANT Stock. The fundamental analysis module provides a way to measure XTANT MEDICAL's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to XTANT MEDICAL stock.
XTANT |
XTANT MEDICAL HLDGS Company Net Asset Analysis
XTANT MEDICAL's Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
| Competition |
Based on the recorded statements, XTANT MEDICAL HLDGS has a Net Asset of 0.0. This indicator is about the same for the Healthcare average (which is currently at 0.0) sector and about the same as Medical Devices (which currently averages 0.0) industry. This indicator is about the same for all Germany stocks average (which is currently at 0.0).
XTANT Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses XTANT MEDICAL's direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of XTANT MEDICAL could also be used in its relative valuation, which is a method of valuing XTANT MEDICAL by comparing valuation metrics of similar companies.XTANT MEDICAL is currently under evaluation in net asset category among its peers.
XTANT Fundamentals
| Return On Equity | -0.26 | |||
| Return On Asset | -0.0619 | |||
| Profit Margin | (0.15) % | |||
| Operating Margin | (0.1) % | |||
| Shares Outstanding | 108.66 M | |||
| Shares Owned By Insiders | 7.59 % | |||
| Shares Owned By Institutions | 75.17 % | |||
| Revenue | 56.67 M | |||
| Gross Profit | 32.49 M | |||
| EBITDA | (4.28 M) | |||
| Net Income | (2.83 M) | |||
| Cash And Equivalents | 20.31 M | |||
| Cash Per Share | 0.23 X | |||
| Total Debt | 17.43 M | |||
| Debt To Equity | 0.51 % | |||
| Current Ratio | 3.83 X | |||
| Book Value Per Share | 0.32 X | |||
| Cash Flow From Operations | 1.79 M | |||
| Earnings Per Share | (0.08) X | |||
| Number Of Employees | 116 | |||
| Beta | 0.63 | |||
| Market Capitalization | 72.54 M | |||
| Z Score | 2.4 |
About XTANT MEDICAL Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze XTANT MEDICAL HLDGS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of XTANT MEDICAL using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of XTANT MEDICAL HLDGS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in XTANT Stock
XTANT MEDICAL financial ratios help investors to determine whether XTANT Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in XTANT with respect to the benefits of owning XTANT MEDICAL security.